Bilateral Cystoid Macular Edema Following Bimatoprost Implants

Patel, Shivam; Badar, Ayesha; Bakhsh, Saaquib; Jusufbegovic, Denis

doi:10.1097/icb.0000000000001346

Cited by 5 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although 1 patient experienced both ME and ocular inflammation during OMDI treatment, both AEs were classified as moderate and were resolved during the study. Similar to the case following OMDI treatment in this study, one case of bilateral ME was reported recently in a patient with POAG following bimatoprost implant injections 17 . In another study of OMDI, all cases of treatment-related ME occurred in eyes with intraocular lens implants 18 .…”

Section: Discussionsupporting

confidence: 86%

“…Similar to the case following OMDI treatment in this study, one case of bilateral ME was reported recently in a patient with POAG following bimatoprost implant injections. 17 In another study of OMDI, all cases of treatment-related ME occurred in eyes with intraocular lens implants. 18 PAPs, such as eyelid pigmentation, eyelash growth, and deepening of the upper eyelid sulcus have been reported with FP agonists, and OMDI is associated with a lower frequency (0%-2%) of these PAPs compared with FP agonists.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Omidenepag Isopropyl in Latanoprost Low/Nonresponders With Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 3, Nonrandomized, Two-Phase, Open-Label Study

Panarelli,

Bowden,

Tepedino

et al. 2023

Journal of Glaucoma

View full text Add to dashboard Cite

Précis: This study demonstrates the efficacy and safety of once-daily 0.002% omidenepag isopropyl (OMDI) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) who do not respond or respond poorly to latanoprost. Purpose: To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of OMDI in latanoprost low/non-responders with POAG or OHT. Materialsand Methods: Phase 3, non-randomized, two-phase, open-label, multicenter study (NCT03697811) in the United States. Key inclusion criteria included individuals aged ≥18 years, POAG or OHT diagnosis in both eyes, IOP ≥22 mm Hg in ≥1 eye and ≤34 mm Hg in both eyes at all time points. Overall, 107 patients were enrolled; 104 completed treatment. Included a screening period (≤35-day washout period and 8-week latanoprost run-in period) and a 3-month treatment period comprising one drop of OMDI 0.002% once daily in both eyes. Primary study endpoint was change from baseline in mean diurnal (MD) IOP at month 3. Safety endpoints included incidence of adverse events (AEs), serious AEs, and adverse drug reactions. Results: At baseline (visit 4), 75 (70.1%) patients had POAG, 32 (29.9%) had OHT, and 68 (63.6%) had prior use of prostaglandin/prostaglandin analogs (37.4% of whom used latanoprost). Mean (standard deviation [SD]) baseline MD IOP was 23.34 mm Hg (2.12). Mean (SD) 3-month (visit 7) MD IOP change from baseline (following latanoprost run-in period and OMDI treatment period) was an additional decrease of 2.96 mm Hg (2.83) (P<0.0001). No significant safety issues were reported during OMDI treatment. Conclusions: These data demonstrate OMDI efficacy and safety in latanoprost low/non-responders with POAG or OHT, suggesting OMDI is a treatment option in the patient population in this study.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 95%

Omidenepag Isopropyl in Latanoprost Low/Nonresponders With Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 3, Nonrandomized, Two-Phase, Open-Label Study

Panarelli,

Bowden,

Tepedino

et al. 2023

Journal of Glaucoma

View full text Add to dashboard Cite

show abstract

“…Patel et al reported also a case report of bilateral CME following bimatoprost implant. 8 The patient was treated with topical corticosteroid with improvement and resolution of the edema.…”

Section: Discussionmentioning

confidence: 99%

Cystoid macular edema occurring after intracameral bimatoprost implantation

Bettach,

Wiener,

Brosh

et al. 2024

European Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose This case report aims to report the development of cystoid macular edema (CME) unilaterally following the administration of bimatoprost implant (Durysta) injections in both eyes for the treatment of primary open-angle glaucoma (POAG). Observations An 84-year-old female patient, previously diagnosed with POAG, underwent bimatoprost implant (Durysta) injections in both eyes, spaced one month apart. Subsequently, the patient experienced a gradual decline in visual acuity in her left eye attributed to the development of CME. The condition resolved following a treatment regimen involving topical dexamethasone and nepafenac. Conclusion The use of bimatoprost implant may lead to the occurrence of CME. Ophthalmologists must vigilantly monitor patients post-implantation, especially if they exhibit visual symptoms or have risk factors for a CME.

show abstract

Bimatoprost

2024

Reactions Weekly

View full text Add to dashboard Cite

Bilateral Cystoid Macular Edema Following Bimatoprost Implants

Cited by 5 publications

References 11 publications

Omidenepag Isopropyl in Latanoprost Low/Nonresponders With Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 3, Nonrandomized, Two-Phase, Open-Label Study

Omidenepag Isopropyl in Latanoprost Low/Nonresponders With Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 3, Nonrandomized, Two-Phase, Open-Label Study

Cystoid macular edema occurring after intracameral bimatoprost implantation

Bimatoprost

Contact Info

Product

Resources

About